NCT03764072

A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy

A Phase 2B Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of VX-150 for Acute Pain Following Bunionectomy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 250 (actual)
• Sponsor: Vertex Pharmaceuticals Incorporated · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the dose-response relationship and safety of VX-150 in treating acute pain following bunionectomy.

Conditions

• Acute Pain

Interventions

Type	Name	Description
DRUG	VX-150	Capsules for oral administration.
DRUG	Placebo	Capsules for oral administration.

Timeline

• Start date: 2018-12-12
• Primary completion: 2019-01-17
• Completion: 2019-01-25
• First posted: 2018-12-04
• Last updated: 2022-02-09
• Results posted: 2022-02-09

Locations

6 sites across 1 country: United States

Regulatory

• FDA-regulated drug study